A significant change is under way as the industry shifts from passive to active trial master file (TMF) management, writes Rik van Mol.
Rik van Mol
Advertisement
Rik van Mol, Vice President of R&D Strategy at Veeva Systems
Articles by Rik van Mol
The pharma industry has had a year to address MHRA’s April 2014 update to the definition of a critical GCP inspection finding to include trial master files(TMFs) that are “not readily available or accessible”. How has it fared? Rik van Mol reports.
Advertisement
Latest Updated Articles
eTMF Adoption a Year After the MHRA UpdatePublished: July 28th 2015 | Updated:
How eTMFs Are Transforming the Pharma IndustryPublished: July 14th 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
